Genmab A/S has entered into a research collaboration with Eli Lilly to use and evaluate Genmab's DuoBody technology platform for the creation of bispecific antibodies. Under the collaboration, Lilly will initially evaluate the DuoBody technology platform in
house. The financial terms of the agreement have not been disclosed. This agreement will not have a material impact on Genmab's financial results and cash position.
Source: Genmab A/S